These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 18922158)

  • 1. Are the adverse effects of glitazones linked to induced testosterone deficiency?
    Carruthers M; Trinick TR; Jankowska E; Traish AM
    Cardiovasc Diabetol; 2008 Oct; 7():30. PubMed ID: 18922158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of glitazones in management of type 2 diabetes. A dream or a nightmare?
    Lindberg M; Astrup A
    Obes Rev; 2007 Sep; 8(5):381-4. PubMed ID: 17716295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Glitazones and congestive heart failure: update on PROactive, ADOPT, DREAM and RECORD clinical trials].
    De Flines J; Scheen AJ
    Rev Med Suisse; 2007 Aug; 3(122):1876, 1878-83. PubMed ID: 17896661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence, Pathophysiology, and Management of Androgen Deficiency in Men with Metabolic Syndrome, Type 2 Diabetes Mellitus, or Both.
    Taylor SR; Meadowcraft LM; Williamson B
    Pharmacotherapy; 2015 Aug; 35(8):780-92. PubMed ID: 26289308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glitazones in type 2 diabetes: an update.
    Drug Ther Bull; 2008 Apr; 46(4):25-9. PubMed ID: 18403615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Heart failure with thiazolidinedione treatment: what do we know today?].
    Erdmann E
    Dtsch Med Wochenschr; 2009 Jan; 134(4):154-8. PubMed ID: 19148858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glitazones in chronic kidney disease: potential and concerns.
    Bolignano D; Zoccali C
    Nutr Metab Cardiovasc Dis; 2012 Mar; 22(3):167-75. PubMed ID: 22364889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency.
    Boyanov MA; Boneva Z; Christov VG
    Aging Male; 2003 Mar; 6(1):1-7. PubMed ID: 12809074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study).
    Hackett G; Cole N; Bhartia M; Kennedy D; Raju J; Wilkinson P; Saghir A;
    Int J Clin Pract; 2014 Feb; 68(2):203-15. PubMed ID: 24355040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome.
    Berria R; Gastaldelli A; Lucidi S; Belfort R; De Filippis E; Easton C; Brytzki R; Cusi K; Jovanovic L; DeFronzo R
    Clin Pharmacol Ther; 2006 Aug; 80(2):105-14. PubMed ID: 16890572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus?
    Consoli A; Formoso G
    Diabetes Obes Metab; 2013 Nov; 15(11):967-77. PubMed ID: 23522285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
    Khanderia U; Pop-Busui R; Eagle KA
    Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The paradox dividing testosterone deficiency symptoms and androgen assays: a closer look at the cellular and molecular mechanisms of androgen action.
    Carruthers M
    J Sex Med; 2008 Apr; 5(4):998-1012. PubMed ID: 18221290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral antidiabetic therapy in patients with heart disease. A cardiologic standpoint.
    Fisman EZ; Tenenbaum A; Motro M; Adler Y
    Herz; 2004 May; 29(3):290-8. PubMed ID: 15167955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The dark side of testosterone deficiency: III. Cardiovascular disease.
    Traish AM; Saad F; Feeley RJ; Guay A
    J Androl; 2009; 30(5):477-94. PubMed ID: 19342698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Update on the Current and Emerging Use of Thiazolidinediones for Type 2 Diabetes.
    Giglio RV; Papanas N; Rizvi AA; Ciaccio M; Patti AM; Ilias I; Pantea Stoian A; Sahebkar A; Janez A; Rizzo M
    Medicina (Kaunas); 2022 Oct; 58(10):. PubMed ID: 36295635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus.
    Defronzo RA; Mehta RJ; Schnure JJ
    Hosp Pract (1995); 2013 Apr; 41(2):132-47. PubMed ID: 23680744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.
    Wang CC; Chen WL; Kao TW; Chang YW; Loh CH; Chou CC
    Clin Ther; 2011 Dec; 33(12):1904-13. PubMed ID: 22118894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Glitazones in type 2 diabetes--documented risks, uncertain benefits].
    Håkansson J
    Lakartidningen; 2007 Oct 24-30; 104(43):3198-200. PubMed ID: 18018937
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluation of metabolite profiles as biomarkers for the pharmacological effects of thiazolidinediones in Type 2 diabetes mellitus patients and healthy volunteers.
    van Doorn M; Vogels J; Tas A; van Hoogdalem EJ; Burggraaf J; Cohen A; van der Greef J
    Br J Clin Pharmacol; 2007 May; 63(5):562-74. PubMed ID: 17488363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.